1.Low Grade Chondrosarcoma Presenting as Progressive Valgus Limb Deformity in a Growing Period.
Hyun Guy KANG ; Weon Seo PARK ; Seog Yun PARK
The Journal of the Korean Bone and Joint Tumor Society 2014;20(1):41-45
A femoral bone tumor causing a valgus deformity by affecting the growth plate was found. Long intramedullary diaphyseal tumor was separated by septum at the metapysis. Low grade chondrosarcoma was confirmed diagnosed by pathologists. Progressive limb deformity can be a sign of bone tumor in growing period.
Chondrosarcoma*
;
Congenital Abnormalities*
;
Extremities*
;
Growth Plate
2.In-vitro cell invasiveness and cytotoxicity of CRMOX-posive and- negative strains of yersinia enterocolitica grown at 26'C and 37'C.
Seog Gee PARK ; Chul Soon CHOI ; Yun Seong JEON
Journal of the Korean Society for Microbiology 1992;27(4):313-324
No abstract available.
Yersinia enterocolitica*
;
Yersinia*
3.Correlation between Clinical Outcome and Proliferation Index in Diffuse Large B-Cell Lymphoma.
Sung Shin PARK ; Joo ryung HUH ; Seung Sook LEE ; Yun Koo KANG ; Dae Seog HEO ; Chul Woo KIM
Korean Journal of Pathology 1999;33(7):475-482
The diffuse large B-cell lymphoma category of the Revised European American Classification of Lymphoid Neoplasms (REAL) encompasses different morphologic lymphoma subtypes in a single entity, especially the diffuse large cell (DLC) and the immunoblastic (IBL) subtypes by Working Formulation (WF). The aim of this study is to determine the influence of the morphologic subdivision within this category with respect to clinical outcome and proliferative index using Ki-67 immunostainig combined with image analysis. We retrospectively reviewed 74 patients from 1990 to 1996, who were diagnosed with diffuse large B-cell lymphoma. All cases were reclassified according to REAL and Working Formulation (WF), and Ki-67 immunostaining was performed in all the cases. Fifty-eight cases (78.4%) were classified as DLC and 16 cases (21.6%) as IBL, according to WF. Twenty one cases (28.4%) showed nodal involvement and 53 cases (71.6%), extranodal involvement. All cases were found to display a variable degree of nuclear Ki-67 staining. A proliferative index of 50% or higher identified a group of patients (77%) who had poor clinical results. Overall survival was significantly reduced in these patients displaying high Ki-67 associated proliferative index compared to those with a low proliferative index (p=0.007). 5-year survival estimates were 93% in the low proliferative index group and 55% in the high proliferative index group. A multivariate regression analysis incorporating commonly used clinical prognostic factors confirmed the independent effect of proliferation index on survival. Moreover, all of the 16 IBL cases showed Ki-67 positivity of 50% or higher, which correlates with the poor clinical outcome compared to 70.7% of DLC (p=0.014). We conclude that subdivision of the diffuse large B-cell lymphoma category of the REAL classification is necessary in terms of prognostic significance in correlation with Ki-67 proliferative index.
B-Lymphocytes*
;
Classification
;
Humans
;
Lymphoma
;
Lymphoma, B-Cell*
;
Lymphoma, Large B-Cell, Diffuse
;
Retrospective Studies
4.Tumors of the Pleura and Lung Developed 17 Years after Allogeneic Bone Marrow Transplantation for Childhood Acute Myelomonocytic Leukemia:Synovial Sarcoma Mimicking Malignant Mesothelioma
Jun Ah LEE ; Bin CHO ; Sun Ah SHIN ; Seog Yun PARK ; Meerim PARK ; Hyeon Jin PARK
Clinical Pediatric Hematology-Oncology 2021;28(1):63-66
Synovial sarcoma occurring in the pleura and lung is extremely rare. We report a case of pleuropulmonary synovial sarcoma as a second malignant neoplasm. The patient had been diagnosed with acute myelomonocytic leukemia at 5 years of age, and received matched sibling donor allogeneic bone marrow transplantation, with total body irradiation and cyclophosphamide conditioning. At 22 years of age, he complained of worsening chest discomfort and exertional dyspnea. Chest CT revealed a huge mass in the right middle lobe, pleura, and diaphragm. The patient was initially diagnosed as sarcomatoid malignant mesothelioma, without any environmental or occupational asbestos exposure. Five months later, the patient presented with soft tissue metastasis and underwent needle biopsy. Pathological examination including SYT-SSX RT-PCR revealed synovial sarcoma, which led to a review of the original tumor findings and confirmed the diagnosis of pleuropulmonary synovial sarcoma.To the best of our knowledge, our patient is the first case of pleuropulmonary synovial sarcoma developed after allogeneic hematopoietic stem cell transplantation.
5.Tumors of the Pleura and Lung Developed 17 Years after Allogeneic Bone Marrow Transplantation for Childhood Acute Myelomonocytic Leukemia:Synovial Sarcoma Mimicking Malignant Mesothelioma
Jun Ah LEE ; Bin CHO ; Sun Ah SHIN ; Seog Yun PARK ; Meerim PARK ; Hyeon Jin PARK
Clinical Pediatric Hematology-Oncology 2021;28(1):63-66
Synovial sarcoma occurring in the pleura and lung is extremely rare. We report a case of pleuropulmonary synovial sarcoma as a second malignant neoplasm. The patient had been diagnosed with acute myelomonocytic leukemia at 5 years of age, and received matched sibling donor allogeneic bone marrow transplantation, with total body irradiation and cyclophosphamide conditioning. At 22 years of age, he complained of worsening chest discomfort and exertional dyspnea. Chest CT revealed a huge mass in the right middle lobe, pleura, and diaphragm. The patient was initially diagnosed as sarcomatoid malignant mesothelioma, without any environmental or occupational asbestos exposure. Five months later, the patient presented with soft tissue metastasis and underwent needle biopsy. Pathological examination including SYT-SSX RT-PCR revealed synovial sarcoma, which led to a review of the original tumor findings and confirmed the diagnosis of pleuropulmonary synovial sarcoma.To the best of our knowledge, our patient is the first case of pleuropulmonary synovial sarcoma developed after allogeneic hematopoietic stem cell transplantation.
6.Utility of H-reflex in the Diagnosis Cervical Radiculopathy.
Jun LEE ; Gun Ju PARK ; Hyun Cheol DOO ; Sung Geon PARK ; Yun Seog JEONG ; Jung Sang HAH
Yeungnam University Journal of Medicine 1997;14(1):111-122
H-reflex is a kind of late respons which can be used for the proximal nerve conduction study. Also it is a useful and widely used nerve conduction technique es to look electrically at the monosynaptic reflex. Although recordable from all muscles theoretically, H-reflexes are most commonly recorded from the calf muscles following stimulation of the tibial nerve in the popliteal fossa. But in this study, We tried to establish the normal data and to evaluate the significance of the H-reflex study in cervical radiculopathy. H-reflexes were recorded from flexor carpi radialis (FCR) muscle, extensor carpi radialis (ECR) muscle, brachioradialis (BR) muscle, and abductor digiti minimi (ADM) muscle in 31 normal adults (62 cases) and 12 patients with cervical radiculopathy. The mean values of H-reflex latency in normal control group were 16.16+/- 1.65 msec in FCR; 15.99+/- 1.25 msec in ECR; 16.47+/- 1.59 msec in BR; 24.46+/- 1.42 msec in ADM. And the mean values of side to side difference of H-reflex latency were 0.47+/- 0.48 msec in FCR; 0.68+/- 0.72 msec in ECR; 0.63+/- 0.43 msec in BR; 22.31+/- 1.24 msec in ADM. Mean values of side to side differences of interlatency time were 0.49+/-0.47 msec in FCR; 0.73+/- 0.62 msec in ECR; 0.79+/- 0.71 msec in BR; 0.69+/- 0.44 msec in ADM. Also, there were no significant differences in H-reflex latency between right and left side. H-reflex tests in patient group with cervical radiculopathy revealed abnormal findings in 11 out of 12 patients. These results suggest that H-reflex in the upper extremity would be helpful in the diagnosis of the cervical radiculopathy.
Adult
;
Male
;
Female
;
Humans
7.Presentation of cancer diagnosis from the patients' point of view.
Young Ho YUN ; Eui Yeol YOON ; Hyeun Ah PARK ; Tae Jin PARK ; Tai Woo YOO ; Bong Yul HUH ; Dae Seog HEO
Journal of the Korean Academy of Family Medicine 1992;13(10):790-799
No abstract available.
Diagnosis*
8.The Clinical Impact of Capmatinib in the Treatment of Advanced Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification
Wonyoung CHOI ; Seog-Yun PARK ; Youngjoo LEE ; Kun Young LIM ; Minjoung PARK ; Geon Kook LEE ; Ji-Youn HAN
Cancer Research and Treatment 2021;53(4):1024-1032
Purpose:
Capmatinib, an oral MET kinase inhibitor, has demonstrated its efficacy against non–small cell lung cancer (NSCLC) with MET dysregulation. We investigated its clinical impact in advanced NSCLC with MET exon 14 skipping mutation (METex14) or gene amplification.
Materials and Methods:
Patients who participated in the screening of a phase II study of capmatinib for advanced NSCLC were enrolled in this study. MET gene copy number (GCN), protein expression, and METex14 were analyzed and the patients’ clinical outcome were retrospectively reviewed.
Results:
A total of 72 patients were included in this analysis (group A: GCN ≥ 10 or METex14, n=14; group B: others, n=58). Among them, 13 patients were treated with capmatinib (group A, n=8; group B, n=5), and the overall response rate was 50% for group A, and 0% for group B. In all patients, the median overall survival (OS) was 20.2 months (95% confidence interval [CI], 6.9 to not applicable [NA]) for group A, and 11.3 months (95% CI, 8.2 to 20.3) for group B (p=0.457). However, within group A, median OS was 21.5 months (95% CI, 20.8 to NA) for capmatinib-treated, and 7.5 months (95% CI, 3.2 to NA) for capmatinib-untreated patients (p=0.025). Among all capmatinib-untreated patients (n=59), group A showed a trend towards worse OS to group B (median OS, 7.5 months vs. 11.3 months; p=0.123).
Conclusion
Our data suggest that capmatinib is a new compelling treatment for NSCLC with MET GCN ≥ 10 or METex14 based on the improved survival within these patients.
9.A Schwannoma of Adrenal Gland.
Yun Seog KANG ; Dong Soo PARK ; Jin Moe LEE ; Hee Jung KIM ; Nam Hoon CHO
Korean Journal of Urology 1995;36(11):1269-1271
Schwannomas are uncommon benign, slowly growing tumors that originate in peripheral, cranial, or autonomic nerves and are composed of Schwann cells in a collagenous matrix. Retroperitoneum is often the site of occurrence of schwannoma, but report on schwannoma of the adrenal gland is rare. We report a case of adrenal schwannoma. A 53 male had facial edema and paresthesia of extremities for 3 month. Incidentally adrenal mass was found on abdominal computer tomogram and exploration performed.
Adrenal Glands*
;
Autonomic Pathways
;
Collagen
;
Edema
;
Extremities
;
Humans
;
Male
;
Neurilemmoma*
;
Paresthesia
;
Schwann Cells
10.Systems Biology Approaches to Decoding the Genome of Liver Cancer.
Ju Seog LEE ; Ji Hoon KIM ; Yun Yong PARK ; Gordon B MILLS
Cancer Research and Treatment 2011;43(4):205-211
Molecular classification of cancers has been significantly improved patient outcomes through the implementation of treatment protocols tailored to the abnormalities present in each patient's cancer cells. Breast cancer represents the poster child with marked improvements in outcome occurring due to the implementation of targeted therapies for estrogen receptor or human epidermal growth factor receptor-2 positive breast cancers. Important subtypes with characteristic molecular features as potential therapeutic targets are likely to exist for all tumor lineages including hepatocellular carcinoma (HCC) but have yet to be discovered and validated as targets. Because each tumor accumulates hundreds or thousands of genomic and epigenetic alterations of critical genes, it is challenging to identify and validate candidate tumor aberrations as therapeutic targets or biomarkers that predict prognosis or response to therapy. Therefore, there is an urgent need to devise new experimental and analytical strategies to overcome this problem. Systems biology approaches integrating multiple data sets and technologies analyzing patient tissues holds great promise for the identification of novel therapeutic targets and linked predictive biomarkers allowing implementation of personalized medicine for HCC patients.
Biomarkers
;
Breast
;
Breast Neoplasms
;
Carcinoma, Hepatocellular
;
Child
;
Clinical Protocols
;
Epidermal Growth Factor
;
Epigenomics
;
Estrogens
;
Gene Expression Profiling
;
Genome
;
Genomics
;
Humans
;
Precision Medicine
;
Liver
;
Liver Neoplasms
;
Oligonucleotide Array Sequence Analysis
;
Prognosis
;
Proteomics
;
Systems Biology